title: Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
abstract: Cardiotoxicity is one of the main limiting side effects of doxorubicin and cyclophosphamide (DC) treatment, and this study was organized to identify cardioprotective activity of amifostine and dexrazoxane against DC combination. BalbC/NIH mice underwent DC treatment (DC group), were pre-treated with amifostine (ADC group) or dexrazoxane (IDC group) and were killed at 1.5 and 3 months after treatments when the grade of myocardial damage was analysed by light microscopy using the Billingham scoring method. DC treatment induced severe myocardial damage with one lethal event before evaluation at 3 months. Main characteristics of DC cardiotoxicity were polymorphic myocyte degeneration and alterations in blood vessels followed by ecchymoses, haemorrhage and thromboses. Polymorphism was also found in the IDC and ADC groups, but its morphological patterns were different. In animals subject to IDC treatment, the blood vessels were better preserved than in the ADC group, whereas thrombosis was not seen in either of these two groups. Quantitatively, grade of myocardial injury in the ADC and IDC groups was significantly higher compared with the non-treated group at both times of estimation and significantly lower compared with the DC group at 1.5 months. At 3 months, significance against DC treatment was lost in the ADC group, while preserved in the IDC-treated animals. Also, there was significant progression in the ADC group comparing scores between 1.5 and 3 months. These results revealed that the cardiotoxicity of DC combination displays specific morphological hallmark and evolution in time, different to those described after doxorubicin single treatment. Neither amifostine nor dexrazoxane prevented development of cardiomyopathy induced by DC treatment.
authors.affiliation: Department of Experimental Oncology, National Cancer Research Center, Belgrade, Serbia.
authors.forename: Snezana K
authors.initials: SK
authors.lastname: Bjelogrlic
authors.forename: Silvana T
authors.initials: ST
authors.lastname: Lukic
authors.forename: Slavisa M
authors.initials: SM
authors.lastname: Djuricic
mesh_terms: D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000494:pharmacology; D003520:Cyclophosphamide / Q000009:adverse effects; D064730:Dexrazoxane / Q000494:pharmacology*; D004317:Doxorubicin / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000473:pathology
chemical_list: D002316:Cardiotonic Agents; D004338:Drug Combinations; D064730:Dexrazoxane; D004317:Doxorubicin; D003520:Cyclophosphamide; D004999:Amifostine